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Tenofovir is an effective and widely used antiretroviral drug for the treatment of both human immu-
nodeﬁciency virus (HIV) and hepatitis B virus infection. Although large clinical studies and post-
marketing data support a benign renal proﬁle for tenofovir, numerous cases of kidney injury have raised
concerns about its nephrotoxic potential. Here, we describe the case of a 33-year-old man with HIV who
was treated with tenofovir, following which he developed acute renal failure with proteinuria, gluco-
suria, hypouricemia, hypophosphatemia, and normal anion gap metabolic acidosis, which are suggestive
of acute kidney injury with Fanconi’s syndrome. A renal biopsy revealed acute tubular necrosis with
eosinophilic intracytoplasmic inclusions within the proximal tubular cells. Electron microscopic images
demonstrate giant mitochondria and display prominent clumping, loss, and disorientation of cristae.
After the discontinuation of tenofovir treatment, the patient’s renal function improved and the serum
uric acid and phosphorous levels returned to normal. Tenofovir-induced Fanconi’s syndrome is an
adverse effect that should be considered when prescribing antiretroviral therapy.
Copyright  2014, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Tenofovir is an acyclic nucleotide analog reverse transcriptase
inhibitor approved for the treatment of human immunodeﬁciency
virus (HIV) and hepatitis B virus infections [1]. Tenofovir is elimi-
nated unchanged in the urine by a combination of glomerular
ﬁltration and proximal tubular secretion. Approximately 20e30% of
the drug is actively transported into the renal proximal tubule cells
by organic anion transporters-1 (OAT-1) and to a lesser extent by
OAT-3 in the basolateral membrane. Subsequently, the drug is
secreted into the tubular lumen by multidrug-resistance protein-4
(MRP-4) and MRP-2, which are apical membrane transporters [2].
However, it is believed that tenofovir may cause renal impairment
by inhibiting the activity of DNA polymerase g, which is essentialy, Buddhist Tzu Chi General
aiwan. Tel.: þ886 3 8561825;
.
elief Tzu Chi Foundation. Publishefor mitochondrial replication [3]. We herein present the case of an
HIV-infected patient who developed acute kidney injury with
Fanconi’s syndrome after treatment with tenofovir.2. Case report
A 33-year-old businessman with a known diagnosis of HIV
infection for 7 years presented to our infectious disease clinic with
the chief complaint of foamy urine for 2 months. His current
medications were a regimen of tenofovir, lopinavir, and raltegravir,
which he has been taking for 15 months.
Physical examination revealed only pale conjunctiva. The initial
laboratory blood test results are shown in Table 1. The complete
blood count results during his hospitalization revealed anemia and
lymphopenia. His serum biochemical test results also showed
abnormal renal function with hypouricemia and hypo-
phosphatemia. His blood glucose level was normal and blood
arterial gas analysis conﬁrmed normal anion gap metabolic
acidosis. Urinalysis showed evidence of glycosuria (3þ) and pro-
teinuria (1þ). His 24-hour urine total protein was 3.67 g/day. Thed by Elsevier Taiwan LLC. All rights reserved.
Table 1
Laboratory data of our patient on December 6, 2012, 7 days before stopping
tenofovir.
Item Parameter Parameter
Biochemical
data
White blood
cell
9590/mL Lymphocyte 18.8%
Lymphocyte
CD4%
16% Lymphocyte
CD8%
45%
Neutrophil
cells
71.7% Monocytes 7.1%
Platelet 391,000/mL Hemoglobin 10.9 g/dL
Blood urea
nitrogen
42 mg/dL Creatinine 3.8 mg/dL
Albumin 2.7 g/dL Globulin 5.2 g/dL
Potassium 3.6 mEq/L Sodium 134 mEq/L
Magnesium 2.2 mEq/L Ionized
calcium
1.16 mmol/L
Phosphorous 2.1 mg/dL Uric acid 3.4 mg/dL
Chloride 105 mmol/L Fasting
glucose
107 mg/dL
Urine
biochemical
data
Uric acid 36.2 mg/dL Phosphorous 17.9 mg/dL
Creatinine
b2-microglobulin
53.9 mg/dL
33,571 ng/mL
24 h total
proteinuria
3.67 g/day
Urine
dipstick
pH 5.5 Protein 1þ
Glucose 3þ White blood
cell
3e5/HPF
Red blood cell 0e2/HPF
Arterial
blood gas
pH 7.272 HCO3e 17.2 mmol/L
pO2 91.6 mmHg pCO2 38 mmHg
O2 saturation 95.3%
Normal range of urine b2-microglobulin: 609e2366 ng/mL; lymphocyte percent-
age: 20e45%; lymphocyte CD4 percentage: 29e55%; lymphocyte CD8 percentage:
19e37%.
HPF ¼ high power ﬁeld; pCO2 ¼ partial pressure of carbon dioxide; pO2 ¼ partial
pressure of oxygen.
Fig. 1. (A). A renal biopsy specimen showing normal glomeruli. The arrow shows acute
tubular necrosis and interstitial inﬂammation (hematoxylin and eosin stain at 400).
(B) Eosinophilic intracytoplasmic inclusions (arrow) are seen within the proximal
tubular epithelial cells (hematoxylin and eosin stain 400).
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tion of uric acid was 75.1% (normal range: 6e12%) and fractional
excretion of phosphorus was 60.1% (normal range: 5e20%). Thus,
the clinical picture suggested acute kidney injury with Fanconi’s
syndrome. A renal biopsy demonstrated that the glomeruli were
normal; however, acute tubular necrosis and interstitial inﬂam-
mation were noted (Fig. 1A) along with eosinophilic intra-
cytoplasmic inclusions within the proximal tubular epithelial cells
(Fig. 1B). Electron micrographic ultrastructural ﬁndings showed
enlarged mitochondria (2e6 mmwide; normal mitochondria range
is only 0.5e1 mm wide) with irregular shapes and dysmorphic
mitochondria, which were largely devoid of cristae within the
proximal tubular epithelial cells (Fig. 2). A review of his medica-
tions indicated that tenofovir was the most probable cause of his
symptoms. After discontinuation of tenofovir, the patient’s renal
function improved and serum uric acid and phosphorous returned
to the normal levels after 17 weeks of follow up (Fig. 3). His urine
dipstick test, urine b2-microglobulin level, and 24-hour urine total
protein were all in the normal range.
3. Discussion
Tenofovir, the ﬁrst nucleotidic inhibitor of HIV reverse tran-
scription, became available in 2001. It has been extensively used
worldwide and is now the most prescribed antiretroviral drug [4].
However, reports on its renal safety are still ambiguous. Two
studies have demonstrated tubular dysfunction with tenofovir in
17e22% tenofovir-treated patients [5,6]. The incidence of acute
kidney injury after initiation of tenofovir treatment has varied
greatly, from 1.6/100 person-years to 1.5/1000 person-years [4],
illustrating the inconsistency of reports. Risk factors for developing
tenofovir-associated nephrotoxicity identiﬁed from studies haveincluded increased age, low body weight, pre-existing decrease in
kidney function, low CD4 count, and concomitant use of nephro-
toxic drugs [1,7]. The proximal tubular cell is the main target of
tenofovir toxicity because of its complement of cell membrane
transporters that favor the accumulation of this drug. Unmodiﬁed
tenofovir is excreted in the urine by both glomerular ﬁltration and
tubular secretion. To be secreted, tenofovir enters the epithelial cell
at its basolateral pole using human OAT-1 and to a lesser extent
using human OAT-3. It is then secreted in the tubular lumen
through MRP-2 and MRP-4. When the plasma concentration in-
creases or when apical secretion is inhibited, intracellular concen-
tration of tenofovir increases. This results in partial inhibition of
kidney mitochondrial DNA polymerase g activity, which subse-
quently results in reduction in mitochondrial DNA (as mitochon-
drial replication is affected) and oxidative respiratory chain
dysfunction [2,4]. Mitochondrial structural changes are induced in
the proximal tubular epithelial cells. Because of a shortage of
Fig. 2. Electron micrographic ultrastructural ﬁndings show tenofovir-induced epithe-
lial cell dysfunction due to mitochondrial damage. Enlarged mitochondria (asterisks)
are visible adjacent to normal-sized mitochondria (plus signs). Large mitochondria
appear devoid of cristae, while other mitochondria show normal cristae content
(original magniﬁcation 8000).
Fig. 3. Time course of serum BUN, creatinine, uric acid, and phosphorus levels after
renal biopsy. BUN ¼ blood urea nitrogen; Cre ¼ creatinine.
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ensure reabsorption of ions and small molecules, such as potas-
sium, glucose, phosphate, uric acid, amino acids, and b2-
microglobulin. Therefore, these molecules are secreted in
abnormal quantities in the urine, which is the deﬁnition of
Fanconi’s syndrome [4]. A histological examination mainly reveals
acute tubular necrosis, primarily affecting the proximal tubules.
Tubular ectasia, cytoplasmic simpliﬁcation, prominent nucleoli,
and loss of a brush border indicate a toxic origin. The only sign of
tenofovir-speciﬁc toxicity is giant mitochondria visible as promi-
nent eosinophilic inclusions in the cytoplasm of the proximal
tubular epithelial cells. Some mitochondria are greatly enlarged,
while others appear shrunken. Mitochondrial cristae could be ab-
sent or less abundant than normal, and sometimes grouped at one
pole of the mitochondria [4,7].
Our patient appears to have developed proximal tubular
dysfunction that was ﬁrst evidenced by the presence of glucosuria
with a normal blood glucose level. On further investigation, he was
noted to have a low normal serum phosphate level with a high
fractional excretion of phosphate, low normal serum uric acid with
a high fractional excretion of uric acid, and normal anion gap
metabolic acidosis with a urine pH of 5.5. Further urine studies
showed evidence of signiﬁcant proteinuria (3.67 g/day), with only
1þ albuminuria on a urine dipstick, which suggested a tubular
source of the proteinuria. This was further supported by the high
level of urinary b2-microglobulin (33,571 ng/mL). This constella-
tion of blood and urinary derangements coupled with the proximal
tubular epithelial cells in the urinary sediment is consistent with
proximal tubular injury and Fanconi’s syndrome. The patient had
been taking tenofovir, raltegravir, and lopinavir for 15 months
before admission. Raltegravir is a type of integrase inhibitor and
was associated with rhabdomyolysis and renal dysfunction in three
cases [8]. Lopinavir belongs to the family of protease inhibitors, and
has been reported to cause renal dysfunction when boosted by ri-
tonavir [9]. HIV-associated nephropathy is the most common cause
of chronic kidney disease in HIV-infected persons who are not
receiving highly active antiretroviral therapy. HIV mediates dysre-
gulation of glomerular podocytes, the epithelial cells of which
maintain the glomerular basement membrane, and apoptosis of
renal tubular cells. The resulting lesions of HIV-associated ne-
phropathy are a focal segmental glomerulosclerosis [10]. Renal
W.-S. Tsai et al. / Tzu Chi Medical Journal 27 (2015) 83e8686biopsy in our patient revealed toxic acute tubular necrosis with
eosinophilic intracytoplasmic inclusions within the proximal
tubular cells. An electron microscopic examination demonstrated
abnormal mitochondria with disruption of the normal cristae,
consistent with tenofovir toxicity. All the data pointed to tenofovir-
induced Fanconi’s syndrome with acute renal failure. After
discontinuation of tenofovir, the patient’s renal function and Fan-
coni’s syndrome improved after 17 weeks of follow up.
In summary, we reported a patient with tenofovir nephropathy
who presented with acute renal failure with Fanconi’s syndrome. A
high index of suspicion may help prevent tenofovir nephropathy. It
is possible to signiﬁcantly reduce this risk by observing simple
rules, such asmeasuring kidney function carefully, assessing kidney
disease risk before prescription, and screening for abnormal prox-
imal tubule function, which may be assessed by measuring tubular
protein excretion and fractional urinary excretion of phosphate or
uric acid, and using a dipstick to test for urinary glucose.
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